US 11,708,352 B2
Anti-cancer compounds
Csaba J. Peto, San Francisco, CA (US); David Jablons, San Francisco, CA (US); and Hassan Lemjabbar-Alaoui, San Francisco, CA (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed on Oct. 15, 2021, as Appl. No. 17/502,954.
Application 17/502,954 is a continuation of application No. 16/790,287, filed on Feb. 13, 2020, granted, now 11,149,025, issued on Oct. 19, 2021.
Application 16/790,287 is a continuation of application No. 15/574,101, granted, now 10,562,886, issued on Feb. 18, 2020, previously published as PCT/US2016/033806, filed on May 23, 2016.
Claims priority of provisional application 62/164,745, filed on May 21, 2015.
Prior Publication US 2022/0267307 A1, Aug. 25, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 403/04 (2006.01); A61K 31/502 (2006.01); A61P 35/00 (2006.01); C07D 401/14 (2006.01); C07D 403/14 (2006.01)
CPC C07D 403/04 (2013.01) [A61K 31/502 (2013.01); A61P 35/00 (2018.01); C07D 401/14 (2013.01); C07D 403/14 (2013.01)] 19 Claims
 
1. A compound, or a salt or a hydrate or a solvate thereof, having a structure according to formula (XIII):

OG Complex Work Unit Chemistry
wherein Z is —O— or —CH2— or —NH— or —N(CH2R5)— wherein R5 is hydrogen or substituted or unsubstituted C1 or C2 or C3 or C4 or C5 or C6 or C7 or C8 or C9 or C10 alkyl; R1 is substituted or unsubstituted C1 or C2 or C3 or C4 or C5 or C6 or C7 or C8 or C9 or C10 alkyl; R2 is hydrogen or methyl or ethyl or propyl or isopropyl or halogen; R3 is chloro; R4 is chloro.